Karo Healthcare Limited has appointed Michael Kaltenborn as Chief Strategy Corporate Development Officer (CSDO). The appointment of Michael Kaltenborn reflects Karo's ambition to grow via MA and to continue to acquire attractive consumer healthcare brands and portfolios. The appointment strengthens the international profile of Karo's organization and leadership team.

Michael joins Karo from Bayer where he headed Consumer Healthcare MA and was also responsible for the Commercial Evaluation, Separation Integration and Health, Safety Environment functions. During his 15 years at Bayer, Michael built an extensive MA toolbox, across a range of transactions, including: the sale of Derm Rx (Intendis) to Leo Pharma in 2018, the divestment of Currenta to Macquarie, the divestment of Coppertone to Beiersdorf and of Dr. Scholl's to Yellowwood in 2019, the acquisition of Care /Of in 2020 and the acquisition of Gloryfeel Natsana, which were foundational for Bayer's European e-commerce entry, in 2021/22. Prior to Bayer, Michael spent 5 years at EY as a member of the Transaction Services team.

Michael, a German citizen, holds a master's degree in Business Administration and Management from the University of Munster, Germany. Michael will join Karo on February 1, 2023, and will be a part of the Corporate Management Team, reporting to Christoffer Lorenzen, CEO. Michael replaces Carl Lindgren who has worked with Karo since 2017.

Carl has been instrumental in Karo's growth journey and has spearheaded an expansive MA agenda, which has increased the company by 4x in size during his tenure. Carl leaves Karo as part of a planned succession to pursue private investment projects and Board roles.